Is my problem low desire/arousal or erectile mechanics — and which treatment actually fits?

The short answer

Two different problems get lumped together as "sexual dysfunction," and treating them with the wrong tool is why people conclude "nothing works."

Erectile dysfunction (ED) is a vascular/mechanical problem — the blood-flow machinery that produces an erection isn't working, even when desire and arousal are present. Tools: PDE5 inhibitors (Viagra/sildenafil, Cialis/tadalafil), which improve blood flow.

Low arousal / desire is a central problem — the brain isn't generating the desire or arousal signal in the first place. Tools: PT-141 (bremelanotide), which acts on brain melanocortin pathways to generate arousal.

These are upstream (desire) and downstream (mechanics) parts of the same sexual-response cascade. A PDE5 inhibitor fixes the plumbing; it can't create water pressure that isn't there. PT-141 generates the upstream signal; it doesn't fix broken plumbing.

This piece helps you figure out which problem you actually have and which tool fits. For the broader context see the Sexual health peptides cornerstone.

Evidence tier: 2 — the mechanistic distinction between central arousal pathways and peripheral vascular function is well-established pharmacology and physiology.

The sexual-response cascade

Evidence tier: 2 — established sexual-medicine physiology.

Sexual response in simplified form runs:

1. Desire — the wish for sexual activity (central, brain-driven; hormones + neurotransmitters + psychology) 2. Arousal — the physical and mental activation in response to stimuli (central + peripheral) 3. Erection / lubrication — the mechanical/vascular response (peripheral, blood-flow-driven) 4. Orgasm — (central + peripheral)

PDE5 inhibitors act at stage 3 (the vascular/mechanical step). PT-141 acts at stages 1–2 (desire/arousal, central).

If your problem is at stage 3 — desire and arousal are fine, but the erection won't come or won't hold — a PDE5 inhibitor is the right tool.

If your problem is at stages 1–2 — the desire/arousal isn't there to begin with — a PDE5 inhibitor has nothing to work with, and PT-141 (or hormone optimization, or addressing a psychological/medication cause) is more relevant.

How to tell which problem you have

Evidence tier: 3 — clinical self-assessment heuristics; proper diagnosis requires a physician.

A rough self-assessment (not a substitute for clinical evaluation):

Signs the problem is erectile/vascular (stage 3): - You have desire and feel aroused, but can't achieve or maintain an erection even when aroused - The difficulty is consistent regardless of partner or situation - You have cardiovascular risk factors (diabetes, hypertension, atherosclerosis) — ED is often an early vascular-disease marker - Spontaneous erections (morning, sleep) are also diminished

Signs the problem is desire/arousal (stages 1–2): - You still get spontaneous erections (morning wood, during sleep) but struggle in the moment - You've noticed declining interest/desire rather than mechanical failure - The issue tracks with stress, relationship changes, mood, or starting a medication (especially SSRIs) - Desire is situation-dependent (fine in some contexts, absent in others)

Both can coexist, especially with age, chronic disease, or TRT. And the self-assessment is rough — a urologist or sexual-medicine physician can distinguish them properly, including nocturnal-tumescence testing (which checks whether the vascular machinery works during sleep, isolating the vascular question from the desire question).

Why this distinction trips people up

Evidence tier: 3 — clinical-practice observation.

The default cultural script is "sexual problem → Viagra." For the large subset of people whose actual issue is desire/arousal rather than erectile mechanics, this leads to a predictable failure:

1. Person notices sexual difficulty 2. Gets a PDE5 inhibitor (from a doctor, a telehealth service, or a friend) 3. It doesn't help, because their problem was upstream (desire), not downstream (mechanics) 4. Concludes "nothing works" or "it must be psychological/permanent"

The fix is recognizing that the wrong-mechanism tool was used. PT-141 exists precisely for the desire/arousal problem that PDE5 inhibitors don't touch. This is why the FDA approved it (as Vyleesi) for hypoactive sexual desire disorder specifically — a desire problem, not a mechanical one.

When to use which tool

Evidence tier: 2 for the individual tools; Tier 3 for the decision rules.

| Your problem | Right tool | Mechanism | |--------------|-----------|-----------| | Erection won't come/hold, desire intact | PDE5 inhibitor (Viagra/Cialis) | Vascular blood flow | | Low desire/arousal, mechanics intact | PT-141 (or hormone/psych workup) | Central arousal signaling | | Both | PT-141 + PDE5 inhibitor (clinically guided) | Both pathways | | Low desire from low testosterone | TRT first, then reassess | Hormonal | | Low desire from SSRIs | Address the medication; PSSD workup | Medication-induced | | Performance anxiety / psychological | Therapy ± as-needed PDE5 inhibitor for confidence | Psychological |

The decision starts with correctly identifying the problem, which is why a proper workup beats guessing. But the broad rule: desire/arousal problem → PT-141 is the relevant peptide; erectile/vascular problem → PDE5 inhibitor.

Combining the two

Evidence tier: 3 — practitioner reasoning; blood-pressure interaction warrants clinical input.

For people with both desire and erectile components — common with age, TRT, or chronic disease — PT-141 (arousal) + a PDE5 inhibitor (mechanics) addresses both.

The caution is blood pressure. PT-141 transiently raises it; PDE5 inhibitors can lower it. The combined cardiovascular effect isn't fully characterized, so combining them warrants physician guidance on timing and dosing. Don't self-combine casually. See the PT-141 complete guide for the combination detail.

Is low arousal "all in your head"?

Evidence tier: 2 — multiple validated causal pathways for low desire/arousal.

No. Low desire/arousal has multiple causes, and the "it's psychological" framing is often wrong:

• Hormonal — low testosterone, thyroid dysfunction, elevated prolactin
• Neurological — the central melanocortin pathway PT-141 targets; other neurotransmitter systems
• Medication-induced — SSRIs are a major cause (and can cause persistent dysfunction after stopping — PSSD; see PSSD recovery)
• Psychological — stress, depression, relationship factors, performance anxiety
• Vascular spillover — sometimes early vascular disease presents as reduced arousal before overt ED

A proper workup distinguishes these, which determines whether the right path is PT-141, hormone optimization, medication adjustment, or therapy. The point: don't accept "it's all in your head" without a real evaluation, and don't assume a peptide is the answer before the cause is identified.

The female version of this distinction

Evidence tier: 2 — female sexual dysfunction has analogous desire-vs-response subtypes.

Female sexual dysfunction splits similarly:

• Hypoactive sexual desire disorder (HSDD) — the desire side. This is what PT-141/Vyleesi is FDA-approved for.
• Arousal/lubrication disorders — closer to the "mechanics" side; local treatments, hormones, or other approaches fit better.

The desire-vs-mechanics framing applies to women too, with PT-141 targeting the desire side specifically. See sexual health peptides for women for the female-specific breakdown.

Limitations

This is an evidence-based framing piece, not personalized medical advice.

• Proper diagnosis requires a physician. The self-assessment heuristics are rough; a urologist or sexual-medicine specialist can distinguish the subtypes properly.
• ED can be an early cardiovascular-disease marker — new-onset ED warrants a cardiovascular workup, not just a PDE5 prescription.
• Cardiovascular screening before PT-141 is mandatory; it raises blood pressure transiently.
• Combining PT-141 + PDE5 inhibitors warrants clinical guidance (blood-pressure interaction).
• Pregnancy and breastfeeding are contraindications for PT-141.
• Marko Maal, MSc Pharmacy reviewed this article. Reviewer attribution does not constitute a doctor-patient relationship.

The bottom line

Erectile dysfunction and low arousal/desire are different problems requiring different tools. ED is vascular — PDE5 inhibitors fix the mechanics. Low arousal is central — PT-141 generates the desire signal that the mechanics then act on. Using a PDE5 inhibitor for a desire problem is the most common reason people conclude "nothing works."

Identify which problem you actually have (ideally with a physician), then match the tool to the mechanism. For mixed presentations, the two can be combined under clinical guidance.

Related on this site

• Sexual health peptides cornerstone
• PT-141 complete guide
• Sexual health peptides for women
• TRT + sexual health
• PSSD recovery
• Main PT-141 peptide page
• Sexual Health pillar hub

References

• McMahon CG. 2019. Current diagnosis and management of erectile dysfunction. Med J Aust. 210(10):469-476. PMID 31099420 — ED diagnosis + vascular-marker framing.
• Kingsberg SA, Clayton AH, Portman D, et al. 2019. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder (RECONNECT). Obstet Gynecol. 134(5):899-908. PMID 31599832 — PT-141 for the desire/arousal problem specifically.
• Molinoff PB, Shadiack AM, Earle D, Diamond LE, Quon CY. 2003. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Ann N Y Acad Sci. 994:96-102. PMID 12851303 — central-arousal mechanism.
• Goldstein I, Lue TF, Padma-Nathan H, et al. 1998. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med. 338(20):1397-1404. PMID 9580646 — foundational PDE5-inhibitor vascular-mechanism evidence.